Management of atrial fibrillation: Translating clinical trial data into clinical practice

American Journal of Medicine

Volumn 124, Issue 1, 2011, Pages 4-14

  Eagle, Kim A ^a   Cannom, David S ^b   Garcia, David A ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Management; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; APIXABAN; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DABIGATRAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PLACEBO; PROPAFENONE; RIVAROXABAN; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TEDISAMIL; UNINDEXED DRUG; VERNAKALANT; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CALCIUM CELL LEVEL; CARDIOLOGIST; CARDIOVERSION; CATHETER ABLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXERCISE TOLERANCE; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; INTERNAL MEDICINE; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TOXICITY; MAINTENANCE THERAPY; MONOMORPHIC VENTRICULAR TACHYCARDIA; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PATHOPHYSIOLOGY; PHLEBITIS; PHOTOSENSITIVITY; PHYSICIAN; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VISUAL DISORDER; XEROSTOMIA;

ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; ELECTRIC COUNTERSHOCK; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HEART RATE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 78650726921     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.05.016     Document Type: Review

References (91)

1. R.W. Rho, and R.L. Page Asymptomatic atrial fibrillation Prog Cardiovasc Dis 48 2005 79 87
2. M. Cohen, and G.V. Naccarelli Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm J Cardiovasc Electrophysiol 19 2008 885 890
3. V. Fuster, L.E. Rydn, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Eur Heart J 27 2006 1979 2030 (Pubitemid 44313588)
4. T.S. Tsang, Y. Miyasaka, M.E. Barnes, and B.J. Gersh Epidemiological profile of atrial fibrillation: a contemporary perspective Prog Cardiovasc Dis 48 2005 1 8
5. M.C. Wijffels, C.J. Kirchhof, R. Dorland, and M.A. Allessie Atrial fibrillation begets atrial fibrillation A study in awake chronically instrumented goats Circulation 92 1995 1954 1968
6. C.A. Morillo, G.J. Klein, D.L. Jones, and C.M. Guiraudon Chronic rapid atrial pacing Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation Circulation 91 1995 1588 1595
7. J. Ausma, M. Wijffels, and F. Thon Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat Circulation 96 1997 3157 3163
8. M. Allessie, J. Ausma, and U. Schotten Electrical, contractile and structural remodeling during atrial fibrillation Cardiovasc Res 54 2002 230 246
9. B.A. Schoonderwoerd, I.C. Van Gelder, and D.J. Van Veldhuisen Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation Prog Cardiovasc Dis 48 2005 153 168
10. W.J. Manning, D.I. Silverman, and S.E. Katz Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation J Am Coll Cardiol 23 1994 1535 1540
11. M.R. Franz, P.L. Karasik, and C. Li Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter J Am Coll Cardiol 30 1997 1785 1792
12. B.J. Brundel, I.C. Van Gelder, and R.H. Henning Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation Circulation 103 2001 684 690
13. Y. Miyasaka, M.E. Barnes, and B.J. Gersh Changing trends of hospital utilization in patients after their first episode of atrial fibrillation Am J Cardiol 102 2008 568 572
14. J.Y. Le Heuzey, O. Paziaud, and O. Piot Cost of care distribution in atrial fibrillation patients: the COCAF study Am Heart J 147 2004 121 126
15. G. Thrall, D. Lane, D. Carroll, and G.Y. Lip Quality of life in patients with atrial fibrillation: a systematic review Am J Med 119 2006 448.e1 448.e19
16. E.Q. Wu, H.G. Birnbaum, and M. Mareva Economic burden and co-morbidities of atrial fibrillation in a privately insured population Curr Med Res Opin 21 2005 1693 1699
17. A. Shiroshita-Takeshita, B.J. Brundel, and S. Nattel Atrial fibrillation: basic mechanisms, remodeling and triggers J Interv Card Electrophysiol 13 2005 181 193 (Pubitemid 41372065)
18. A.L. Wit, and P.A. Boyden Triggered activity and atrial fibrillation Heart Rhythm 4 3 Suppl 2007 S17 S23
19. J. Xu, G. Cui, and F. Esmailian Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation Circulation 109 2004 363 368
20. Y. Nakano, S. Niida, and K. Dote Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation J Am Coll Cardiol 43 2004 818 825
21. W. Wongcharoen, and S.A. Chen Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation Expert Rev Cardiovasc Ther 7 2009 311 322
22. D. Li, S. Fareh, T.K. Leung, and S. Nattel Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort Circulation 100 1999 87 95
23. T. Ohkusa, T. Ueyama, and J. Yamada Alterations in cardiac sarcoplasmic reticulum Ca2+ regulatory proteins in the atrial tissue of patients with chronic atrial fibrillation J Am Coll Cardiol 34 1999 255 263
24. S. Lvy, M. Maarek, P. Coumel The College of French Cardiologists Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study Circulation 99 1999 3028 3035
25. W.B. Kannel, and E.J. Benjamin Current perceptions of the epidemiology of atrial fibrillation Cardiol Clin 27 2009 13 24
26. H.J. Crijns Rate versus rhythm control in patients with atrial fibrillation: what the trials really say Drugs 65 2005 1651 1667
27. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
28. P. Dorian, W. Jung, and D. Newman The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy J Am Coll Cardiol 36 2000 1303 1309
29. D.G. Wyse, A.L. Waldo, and J.P. DiMarco A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
30. G. Opolski, A. Torbicki, and D.A. Kosior Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Chest 126 2004 476 486
31. S.H. Hohnloser, K.H. Kuck, and J. Lilienthal Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 2000 1789 1794
32. I.C. Van Gelder, V.E. Hagens, and H.A. Bosker A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834 1840
33. J. Carlsson, S. Miketic, and J. Windeler Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study J Am Coll Cardiol 41 2003 1690 1696
34. D. Roy, M. Talajic, and S. Nattel Rhythm control versus rate control for atrial fibrillation and heart failure N Engl J Med 358 2008 2667 2677
35. J.S. Steinberg, A. Sadaniantz, and J. Kron Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study Circulation 109 2004 1973 1980
36. V. Snow, K.B. Weiss, and M. LeFevre Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians Ann Intern Med 139 2003 1009 1017
37. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 546S 592S
38. H. Calkins, J. Brugada, and D.L. Packer HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society Europace 9 2007 335 379
39. A.S. Go, E.M. Hylek, and L.H. Borowsky Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
40. A.L. Waldo, R.C. Becker, V.F. Tapson, and K.J. Colgan Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation J Am Coll Cardiol 46 2005 1729 1736
41. A.R. Mitchell Will this be the end of the anticoagulation clinic for patients with atrial fibrillation? Curr Drug Targets Cardiovasc Haematol Disord 5 2005 405 408
42. S. Schulman, R.J. Beyth, C. Kearon, and M.N. Levine Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 257S 298S (Pubitemid 351892969)
43. M.I. Aguilar, R. Hart, and L.A. Pearce Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks Cochrane Database Syst Rev. 2007 Issue 3. Art. No.: CD006186. DOI: 10.1002/14651858. CD006186.pub2.
44. S. Connolly, J. Pogue ACTIVE Writing Group of the ACTIVE Investigators Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
45. J. Mant, F.D. Hobbs, and K. Fletcher Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
46. S.J. Connolly, J. Pogue ACTIVE Investigators Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
47. S.B. Olsson Executive Steering Committee of the SPORTIF III Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
48. G.W. Albers, H.C. Diener, and L. Frison Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
49. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
50. J. Ansell, A. Jacobson, and J. Levy Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation Int J Cardiol 99 2005 37 45
51. D.A. Garcia, D.M. Witt, and E. Hylek Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum Ann Pharmacother 42 2008 979 988
52. C. Lafuente-Lafuente, S. Mouly, and M.A. Longs-Tejero Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials Arch Intern Med 166 2006 719 728
53. D.M. Roden, and M.E. Anderson Proarrhythmia Handb Exp Pharmacol 2006 73 97
54. T.C. Trujillo, and P.E. Nolan Antiarrhythmic agents: drug interactions of clinical significance Drug Saf 23 2000 509 532
55. AFFIRM First Antiarrhythmic Drug Substudy Investigators Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug J Am Coll Cardiol 42 2003 20 29
56. B.N. Singh, S.N. Singh, and D.J. Reda Amiodarone versus sotalol for atrial fibrillation N Engl J Med 352 2005 1861 1872
57. V.R. Vorperian, T.C. Havighurst, S. Miller, and C.T. January Adverse effects of low dose amiodarone: a meta-analysis J Am Coll Cardiol 30 1997 791 798
58. S.H. Hohnloser, H.J. Crijns, and M. van Eickels Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 2009 668 678
59. P. Touboul, J. Brugada, and A. Capucci Dronedarone for prevention of atrial fibrillation: a dose-ranging study Eur Heart J 24 2003 1481 1487
60. B.N. Singh, S.J. Connolly, and H.J. Crijns Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter N Engl J Med 357 2007 987 999
61. S.J. Connolly ATHENA: the effect of dronedarone on cardiovascular outcomes and stroke in patients with atrial fibrillation August 30-September 3, 2008 Presented at the European Society of Cardiology Congress 2008 Munich, Germany
62. L. Køber, C. Torp-Pedersen, and J.J. McMurray Increased mortality after dronedarone therapy for severe heart failure N Engl J Med 358 2008 2678 2687
63. A. Capucci, G.Q. Villani, M.F. Piepoli, and D. Aschieri The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation Curr Opin Cardiol 14 1999 4 8
64. P. Alboni, G.L. Botto, and N. Baldi Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach N Engl J Med 351 2004 2384 2391
65. I.C. Van Gelder, D.G. Wyse, and M.L. Chandler Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies Europace 8 2006 935 942
66. B.N. Singh β-blockers and calcium channel blockers as antiarrhythmic drugs D.P. Zipes, J. Jalife, Cardiac Electrophysiology: From Cell to Bedside 4th edition 2004 W.B. Saunders Philadelphia 918 931
67. J.P. DiMarco Adenosine and digoxin D.P. Zipes, J. Jalife, Cardiac Electrophysiology: From Cell to Bedside 4th edition 2004 W.B. Saunders Philadelphia 942 949
68. H. Calkins New ACC/AHA/ESC guidelines for the management of atrial fibrillation: highlighting stroke prevention and catheter ablation http://cme.medscape.com/viewarticle/543645-print 2006 Accessed April 2009
69. R. Cappato, H. Calkins, and S.A. Chen Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation Circulation 111 2005 1100 1105 (Pubitemid 40365469)
70. R. Kobza, G. Hindricks, and H. Tanner Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment Heart Rhythm 1 2004 676 683
71. B.J. Padanilam, and E.N. Prystowsky Atrial fibrillation: goals of therapy and management strategies to achieve the goals Med Clin North Am 92 2008 217 235
72. M.A. Wood, C. Brown-Mahoney, G.N. Kay, and K.A. Ellenbogen Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis Circulation 101 2000 1138 1144
73. R.N. Goldstein, and B.S. Stambler New antiarrhythmic drugs for prevention of atrial fibrillation Prog Cardiovasc Dis 48 2005 193 208
74. J.S. Healey, A. Baranchuk, and E. Crystal Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis J Am Coll Cardiol 45 2005 1832 1839
75. A.H. Madrid, M.G. Bueno, and J.M. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 2002 331 336
76. K.C. Ueng, T.P. Tsai, and W.C. Yu Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation Results of a prospective and controlled study Eur Heart J 24 2003 2090 2098
77. Y. Yin, D. Dalal, and Z. Liu Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation Eur Heart J 27 2006 1841 1846
78. K. Wachtell, B. Hornestam, and M. Lehto Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study J Am Coll Cardiol 45 2005 705 711 (Pubitemid 40282585)
79. I.R. Hanna, B. Heeke, and H. Bush Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction Heart Rhythm 3 2006 881 886
80. F. Lombardi, and P. Terranova Hypertension and concurrent arrhythmias Curr Pharm Des 9 2003 1703 1713
81. I. Savelieva, and A. John Camm Atrial fibrillation and heart failure: natural history and pharmacological treatment Europace 5 Suppl 1 2004 S5 S19
82. M.R. Movahed, M. Hashemzadeh, and M.M. Jamal Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease Int J Cardiol 105 2005 315 318
83. E.L. Pritchett, P. Kowey, and S. Connolly Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation Maintenance of sinus rhythm after conversion to sinus rhythm Am Heart J 151 2006 1043 1049
84. C.M. Pratt, S.N. Singh, and H.R. Al-Khalidi The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial J Am Coll Cardiol 43 2004 1211 1216
85. F. Lombardi, M. Borggrefe, W. Ruzyllo, and B. Lderitz Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial Eur Heart J 27 2006 2224 2231
86. R.A. VerNooy, and J.M. Mangrum Azimilide, a novel oral class III antiarrhythmic for both supraventricular and ventricular arrhythmias Curr Drug Targets Cardiovasc Haematol Disord 5 2005 75 84
87. S.H. Hohnloser, P. Dorian, and M. Straub Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter J Am Coll Cardiol 44 2004 99 104
88. D. Roy, B.H. Rowe, and I.G. Stiell A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation J Am Coll Cardiol 44 2004 2355 2361
89. D. Roy, C. Pratt, and G. Wyse RSD1235 for conversion of atrial fibrillation, the phase III atrial arrhythmia conversion trial Heart Rhythm 2 2005 1035 Abstract LBA6098
90. C. Pratt, D. Roy, and S. Juul-Moller Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial J Am Coll Cardiol 47 2006 10A Abstract 804-803
91. C.M. Pratt, J. Navratil, and A. Nagy Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion Heart Rhythm 4 Suppl 2007 S176 Abstract PO2-92